BioCryst Pharmaceuticals, Inc. (BCRX) has made great progress in advancing its pipeline. That's because it is currently evaluating the use of oral D Factor inhibitor, known as BCX10013, for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results